Pure Global AI
NCT05705583Recruiting

A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma

Zhejiang Cancer HospitalClinicalTrials.govother
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Other: Blood and Urine Collection
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Zhejiang Cancer Hospital
Location
Hangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2023
End date
Dec 31, 2025
Enrollment
100 participants
Primary outcome

The correlation between the circulating exosomes levels and the tumor responsiveness

Summary

Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials
 showning better response in unselected patients with metastatic renal cell carcinoma (RCC).
 At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 RCC
 responsiveness. The objective of this study is to develop and evaluate the utility of
 circulating exosomes as companion diagnostic biomarker for predicting response to
 immunotherapy in patients with RCC.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05705583
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05705583 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhejiang Cancer Hospital and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.